Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330928 · ClinicalTrials.gov registry record · Phase 2
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
A Phase 2 study, sponsored by Infraredx.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00330928 is a Phase 2 study that has completed, run by Infraredx. The registered enrollment target is 106 participants.
The verdict
NCT00330928, a Phase 2 study, has completed, sponsored by Infraredx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention (PCI).
Interventions
- DEVICE Near Infrared Spectroscopy (NIRS) Imaging
- DEVICE intravascular ultrasound (IVUS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330928
The ClinicalTrials.gov registry entry for NCT00330928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infraredx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Near Infrared Spectroscopy (NIRS) Imaging is the first listed.
NCT00330928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330928 about?
NCT00330928 is a clinical study titled "SPECTACL: SPECTroscopic Assessment of Coronary Lipid". The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention (PCI).
What is the current status of trial NCT00330928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2006-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00330928?
The interventions under investigation include: Near Infrared Spectroscopy (NIRS) Imaging (DEVICE), intravascular ultrasound (IVUS) (DEVICE).
Who is sponsoring clinical trial NCT00330928?
This trial is sponsored by Infraredx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.